GET DAILY SIGNALSLegend Biotech (LEGN) Reports +32% Revenue Growth and Returns to Profitability in Q3 2026
Key Takeaways
- Legend Biotech reported third-quarter 2026 total revenue of $359.5 million, up 32% from $272.4 million a year earlier.
- The company swung to net income of $51.7 million, compared with a net loss of $39.6 million in the prior-year period.
- CARVYKTI net trade sales reached approximately $710 million, growing 36% year over year on continued global demand.
- Gross margin on net product sales improved to 58%, ahead of the lower-50% range the company had guided, driven by manufacturing efficiencies.
- Management reaffirmed its expectation of company-wide profitability for full-year 2026 on an adjusted net income basis.
Why These Results Matter
Legend Biotech is a global cell therapy company best known for CARVYKTI, a CAR-T treatment for multiple myeloma developed and marketed in collaboration with Johnson & Johnson's Janssen unit. Because CARVYKTI accounts for the vast majority of revenue, each quarterly update offers a clear view of the therapy's commercial progress, manufacturing scale-up, and adoption in earlier treatment lines. The third-quarter report carries particular significance after the company's first quarter of overall profitability in Q2 2026 and the recent leadership change, with Ingrid Zhang taking over as chief executive officer effective September 15, 2026. I checked this using Tickeron's AI Screener to see how the stock compares to others in the biotech space. Investors are focused on whether revenue growth, margin gains, and pipeline advances can keep the company on track for full-year profitability.
The Quarter in Numbers
For the third quarter ended September 30, 2026, Legend Biotech reported total revenue of $359.5 million, up 32% from $272.4 million in the same period last year. Net income reached $51.7 million, a sharp turnaround from the net loss of $39.6 million a year earlier.
CARVYKTI net trade sales grew about 36% year over year to roughly $710 million, supported by sustained global demand, earlier-line adoption in the United States, and launches across 20 markets. Gross margin on net product sales rose to 58%, beating the company's prior guidance of the lower-50% range thanks to manufacturing efficiencies. Adjusted net income came in at approximately $55.6 million, versus an adjusted net loss of about $18.7 million in the prior-year quarter.
The company finished the period with roughly $853 million in cash, cash equivalents, and time deposits. Management raised its fourth-quarter gross margin outlook on net product sales to the high-50% range and reaffirmed its goal of full-year 2026 profitability on an adjusted net income basis.
Market Reaction and Sentiment
Before the release, attention centered on whether CARVYKTI could maintain its growth pace after the profitability milestone in the previous quarter. The results showed solid top-line gains and a clear shift to profitability, yet they also pointed to a slowing growth rate for CARVYKTI, with U.S. sales expanding more modestly than in recent periods. Analysts observed that part of the earnings improvement came from a reversal of previously recognized share-based compensation tied to forfeited equity awards rather than core operational strength. As a result, the market has balanced strong profitability against questions about the sustainability of growth, leaving sentiment somewhat mixed after the announcement.
What to Watch in the Quarters Ahead
Several themes stand out for investors to monitor. The pace of earlier-line adoption for CARVYKTI remains key. Management noted that second- and third-line patients made up 50% of U.S. apheresis volume in the third quarter, up from 41% in the first quarter of 2026, and recent guideline updates favoring referral to T-cell therapy centers at first relapse could aid further uptake.
Gross margin will also be closely watched. The company guided to a high-50% range for the fourth quarter, so maintaining manufacturing efficiencies will be important for sustaining profitability.
Pipeline progress is another factor. Legend Biotech received FDA clearance for its investigational new drug application for LB2501, part of its next-generation in vivo cell therapy platform, and continues to advance other programs.
Finally, attention will turn to the leadership transition under new CEO Ingrid Zhang, the balance of U.S. and international growth, and whether the company can meet its reaffirmed target of full-year 2026 adjusted profitability.
Enhancing Analysis with AI Tools
I also checked this using Tickeron's AI Screener to see how the stock compares to others in the industry. The tool helps filter opportunities based on technical patterns, fundamentals, and AI signals, which can make research more efficient when tracking names like this one.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LEGN in upward trend: 10-day moving average crossed above 50-day moving average on October 28, 2026
The 10-day moving average for LEGN crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on LEGN as a result. In 77 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
LEGN moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +7.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where LEGN advanced for three days, in 176 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LEGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
LEGN broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.701) is normal, around the industry mean (3.498). P/E Ratio (-46.800) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2.478) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. LEGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 47 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LEGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a holding company which engages in the discovery and development of novel cell therapies for oncology and other indications
Industry Biotechnology
Advertisement